8-K: Arcturus Reports Q4/FY25 Results, Advances CF & OTC Programs

Arcturus Therapeutics announced its fourth quarter and fiscal year 2025 financial results, highlighting progress in its rare disease pipeline and an extended cash runway.

Summary

• Arcturus Therapeutics reported total revenue of $7.2 million for Q4 2025 and $82.0 million for fiscal year 2025, representing decreases of $15.6 million and $70.3 million, respectively, compared to the same periods in 2024.
• The company's net loss for Q4 2025 was $29.1 million, or ($1.03) per diluted share, an improvement from a net loss of $30.0 million, or ($1.11) per diluted share, in Q4 2024.
• For fiscal year 2025, Arcturus reported a net loss of $65.8 million, or ($2.40) per diluted share, an improvement from a net loss of $80.9 million, or ($3.00) per diluted share, in fiscal year 2024.
• Cash, cash equivalents, and restricted cash stood at $232.8 million as of December 31, 2025, down from $293.9 million as of December 31, 2024.
• The cash runway has been extended into the second quarter of 2028 due to disciplined execution and a strategic refocus on existing rare disease clinical programs.
• ARCT-032, an inhaled mRNA therapeutic for Cystic Fibrosis (CF), is on track to initiate a 12-week Phase 2 clinical study in H1 2026, following positive safety and tolerability data from the 28-day, 15 mg third dosing cohort.
• ARCT-810, an mRNA therapeutic for Ornithine Transcarbamylase (OTC) deficiency, is broadening its development strategy to include both adult late-onset and young children with severe forms, with Type C regulatory meetings on track for H1 2026.
• KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine, received approval from the UK MHRA in January 2026 for individuals aged 18 and older.
• Development of a self-amplifying mRNA pandemic influenza (A/H5N1) vaccine under contract with BARDA continues, with recent 8-month follow-up data showing durable immune response and good tolerability.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. While revenue declined significantly, the company demonstrated strong cost control leading to an improved net loss and successfully extended its cash runway. Crucially, key rare disease pipeline programs are advancing as planned, and a vaccine received regulatory approval, indicating continued execution on strategic priorities.

Positives

• Net loss improved to $29.1 million in Q4 2025 from $30.0 million in Q4 2024, and to $65.8 million in FY 2025 from $80.9 million in FY 2024.
• Cash runway extended into Q2 2028, providing longer financial stability.
• ARCT-032 (CF) Phase 2 third cohort (15 mg, 28 days) demonstrated general safety and good tolerability, allowing progression to a 12-week Phase 2 study.
• ARCT-032 12-week Phase 2 study is on track to initiate in H1 2026, enrolling up to 20 Class I CF participants.
• ARCT-810 (OTC deficiency) development strategy is broadening to address both adult and pediatric populations, with Type C regulatory meetings on track for H1 2026.
• KOSTAIVE, the company's self-amplifying mRNA COVID-19 vaccine, received approval from the UK MHRA in January 2026.
• The self-amplifying mRNA pandemic influenza vaccine showed durable immune response and good tolerability in 8-month follow-up data, supporting the platform's capabilities.

Negatives

• Total revenue for Q4 2025 decreased by $15.6 million to $7.2 million compared to Q4 2024.
• Total revenue for fiscal year 2025 decreased by $70.3 million to $82.0 million compared to fiscal year 2024, primarily due to reductions in the CSL collaboration reflecting lower supply agreement activity and fewer development-based milestone achievements.
• Cash, cash equivalents, and restricted cash decreased to $232.8 million as of December 31, 2025, from $293.9 million as of December 31, 2024.

Risks

• The likelihood of success of the company's pipeline (including ARCT-032 and ARCT-810) and partnered programs (including COVID-19 and flu programs) is uncertain.
• Clinical data, including interim data, may not be predictive of future clinical results.
• There is uncertainty regarding the likelihood of and timing for achieving alignment with regulators on the clinical strategy for ARCT-810.
• The timing for Type C regulatory meetings for ARCT-810 and feedback therefrom may vary.
• The initiation, size, scope, and timing of a Phase 2, 12-week study for ARCT-032 are subject to risks.
• General business and economic conditions may impact the company's operations and financial performance.
• Known and unknown risks, uncertainties, and other factors discussed under 'Risk Factors' in Arcturus' most recent Annual Report on Form 10-K and subsequent SEC filings could materially affect actual results.

Future Outlook

Arcturus expects to align with regulators on its clinical development strategy for the ARCT-810 OTC deficiency program and initiate its Phase 2, 12-week cystic fibrosis study (ARCT-032) in the first half of 2026. Type C regulatory meetings for ARCT-810 and associated feedback are also anticipated in the first half of 2026. The company projects general and administrative expenses to continue to decrease slightly over the next twelve months, driven by lower share-based compensation costs. The current cash position is expected to provide a runway into the second quarter of 2028.

Management Comments

• Joseph Payne, President & CEO, stated: "We look forward to aligning with regulators on our clinical development strategy for the ornithine transcarbamylase (OTC) deficiency program, and to initiating our Phase 2, 12-week cystic fibrosis (CF) study in the first half of 2026."
• Joseph Payne also affirmed: "We remain firmly committed to advancing our once-daily inhaled mRNA therapy for people with cystic fibrosis Class I mutations."

Industry Context

StockSavvy.ai notes that Arcturus Therapeutics operates in the highly competitive and innovative mRNA medicines space, focusing on rare diseases and vaccines. The progress in its CF and OTC programs, alongside the regulatory approval of KOSTAIVE and positive flu vaccine data, positions the company as a key player leveraging its LUNAR lipid-mediated delivery and STARR mRNA technologies. The strategic refocus on rare disease clinical programs and extended cash runway are crucial for sustained development in this capital-intensive industry, especially as larger pharmaceutical companies continue to invest heavily in mRNA platforms.

Comparison to Industry Standards

• NA

Legal Proceedings

• The lawsuit filed by Arcturus against AbbVie Inc. and Capstan Therapeutics, Inc. on September 23, 2025, in the U.S. District Court for the Southern District of California remains ongoing.

Stakeholder Impact

• Shareholders: Potential positive impact from pipeline progress, extended cash runway, and improved net loss, balanced against significant revenue decline.
• Patients (CF and OTC deficiency): Positive impact from the advancement of ARCT-032 and ARCT-810, offering hope for new therapeutic options.
• Employees: Operational restructuring mentioned as a factor in reduced payroll and benefits, indicating potential past or ongoing workforce adjustments.
• Regulatory Authorities: Continued engagement with regulators for ARCT-810 and successful approval of KOSTAIVE demonstrate adherence to regulatory processes.

Next Steps

• Initiate a Phase 2, 12-week clinical study for ARCT-032 in H1 2026, enrolling up to 20 Class I CF participants.
• Conduct Type C regulatory meetings with health authorities for ARCT-810 in H1 2026 to discuss pivotal study strategies.
• Continue development of the self-amplifying mRNA pandemic influenza vaccine under the BARDA contract.

Key Dates

Recommendation

The filing presents a mixed financial picture with a significant revenue decline but also improved net loss and an extended cash runway, demonstrating effective cost management. The substantial progress in the rare disease pipeline (ARCT-032 and ARCT-810) and the regulatory approval of KOSTAIVE are strong operational positives. However, the revenue decrease, primarily from the CSL collaboration, indicates a shift in revenue streams post-commercialization of KOSTAIVE. A 'hold' recommendation is appropriate as the company navigates this transition, with pipeline advancements offering future upside potential, but current revenue trends warrant caution until new revenue drivers materialize or existing collaborations expand.

Keywords

Arcturus Therapeutics, ARCT, mRNA therapeutics, Cystic Fibrosis, ARCT-032, Ornithine Transcarbamylase Deficiency, ARCT-810, Rare Disease, COVID-19 vaccine, KOSTAIVE, Pandemic Flu vaccine, BARDA, Financial Results, Biotechnology, Clinical Trials, Drug Development, SEC Filing